Considering VEGF’s enhancement of mini-dystrophin gene therapy efficacy [8] and Ang 1’s anti-inflammatory properties, Ang 1 may prove invaluable as an adjunct vascular-therapeutic agent for treating DMD. This evidence concerns the gene VEGFA and Duchenne muscular dystrophy.